EP
VRTX icon

Edgestream Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Edgestream Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$769K Sell
1,549
-1,714
-53% -$760K 0.02% 716
2026
Q1 		$1.46M Sell
3,263
-3,440
-51% -$1.6M 0.05% 568
2025
Q4 		$3.04M Sell
6,703
-1,043
-13% -$450K 0.09% 419
2025
Q3 		$3.03M Buy
7,746
+1,331
+21% +$556K 0.09% 416
2025
Q2 		$2.86M Buy
6,415
+5,677
+769% +$2.62M 0.08% 449
2025
Q1 		$358K Sell
738
-5,104
-87% -$2.38M 0.01% 732
2024
Q4 		$2.35M Buy
5,842
+3,640
+165% +$1.69M 0.1% 363
2024
Q3 		$1.02M Sell
2,202
-464
-17% -$223K 0.05% 566
2024
Q2 		$1.25M Sell
2,666
-9,988
-79% -$4.34M 0.06% 466
2024
Q1 		$5.29M Buy
12,654
+11,908
+1,596% +$5.03M 0.26% 92
2023
Q4 		$304K Sell
746
-2,656
-78% -$981K 0.02% 718
2023
Q3 		$1.18M Buy
3,402
+982
+41% +$343K 0.09% 344
2023
Q2 		$852K Buy
+2,420
New +$815K 0.08% 394
2022
Q4 		– Sell
-5,068
Closed -$1.47M – 648
2022
Q3 		$1.47M Buy
5,068
+2,303
+83% +$663K 0.11% 233
2022
Q2 		$779K Buy
+2,765
New +$740K 0.06% 360
2022
Q1 		– Sell
-1,457
Closed -$320K – 645
2021
Q4 		$320K Sell
1,457
-3,475
-70% -$676K 0.02% 433
2021
Q3 		$895K Buy
+4,932
New +$963K 0.06% 331
2019
Q2 		– Sell
-7,540
Closed -$1.39M – 291
2019
Q1 		$1.39M Buy
+7,540
New +$1.39M 0.2% 114
2018
Q3 		– Sell
-7,789
Closed -$1.32M – 341
2018
Q2 		$1.32M Buy
+7,789
New +$1.21M 0.27% 125

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Edgestream Partners's VRTX Position: Q2 2026 in Review

Edgestream Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 53% in Q2 2026, selling an estimated $760K and leaving 1,549 shares worth $769K. The position accounts for 0.02% of the portfolio, ranked #716.

Edgestream Partners first reported a position in VRTX in Q2 2018 and has held it in 19 quarters since. The position peaked at $5.29M in Q1 2024. 1,756 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Edgestream Partners held 1,549 shares of Vertex Pharmaceuticals worth $769K as of Q2 2026.
  • Edgestream Partners sold 1,714 Vertex Pharmaceuticals shares in Q2 2026, an estimated $760K.
  • Vertex Pharmaceuticals made up 0.02% of Edgestream Partners's portfolio in Q2 2026, its #716 holding.
  • Edgestream Partners first reported a position in Vertex Pharmaceuticals in Q2 2018 and has held it in 19 quarters since.
  • Edgestream Partners's Vertex Pharmaceuticals position peaked at $5.29M in Q1 2024.
  • 1,756 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.